000 | 01242 a2200337 4500 | ||
---|---|---|---|
005 | 20250515091534.0 | ||
264 | 0 | _c20080904 | |
008 | 200809s 0 0 eng d | ||
022 | _a0344-5704 | ||
024 | 7 |
_a10.1007/s00280-007-0616-3 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMeany, Holly J | |
245 | 0 | 0 |
_aThe plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. _h[electronic resource] |
260 |
_bCancer chemotherapy and pharmacology _cAug 2008 |
||
300 |
_a387-92 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aArea Under Curve |
650 | 0 | 4 | _aErlotinib Hydrochloride |
650 | 0 | 4 | _aInjections, Intravenous |
650 | 0 | 4 | _aMacaca mulatta |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMetabolic Clearance Rate |
650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
700 | 1 | _aFox, Elizabeth | |
700 | 1 | _aMcCully, Cynthia | |
700 | 1 | _aTucker, Chris | |
700 | 1 | _aBalis, Frank M | |
773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 62 _gno. 3 _gp. 387-92 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-007-0616-3 _zAvailable from publisher's website |
999 |
_c17453408 _d17453408 |